Evofem Biosciences, Inc. (EVFM) income statement
EVFMOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$0.01−0.00 (-10.00%)
Close on Oct 19, 2026Market cap $865.23KP/E –Yield –
Evofem Biosciences, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 75.5%
- Operating margin
- -15.3%
- Net margin
- -84.7%
- Return on equity, FY2025
- -0.5%
Financial strength
- Current ratio
- 0.07
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 0.3%
Valuation
- P/E ratio
- –
- Price to sales
- 0.05
- Price to book
- –
- Dividend yield
- –
See a number that looks wrong?